United States Patent 5,145,863 Landscape: Scope and Claim-Chart Grade Patentability Boundaries for Tumor-Localized Fluorescent Photosensitizing Porphyrin/Chlorin Aggregates
United States Patent 5,145,863 protects methods of destroying or impairing target biological materials (read: therapeutic photodynamic action in tissue) using fluorescent, photosensitizing tumor-localizing conjugates. The key claim scope is built on (1) chemical architecture (multi-porphyrin or multi-chlorin conjugates with specific heteroaromatic unit formulas), (2) biophysical self-association behavior (aqueous aggregates >10 kDa that dissociate in tissue), and (3) photophysical constraints (triplet energy >37.5 kcal/mol, not readily oxidized, and not physically quenching required energy states). Dependent claims add excipient inclusion and administering to a subject.
This estate is unusually narrow in functional chemistry but broad in therapeutic framing. It is also “claim-set dense” around aggregate size, tissue dissociation, and triplet-energy/oxidation/quenching limitations, which are typically where design-arounds succeed.
1. What does US 5,145,863 claim protect and what is the core inventive concept?
Core protection (independent claims 1, 4, 7, 10, 13):
A method to “destroy or impair” biological targets by contacting them with a biologically active composition having:
- Fluorescence + photosensitization
- Tumor localization and retention in tumor tissue vs normal tissues
- Conjugate architecture
- Multi porphyrin conjugates (claim 1 and porphyrin compositions in claim 10, porphyrin mixture in claim 13)
- Multi chlorin conjugates (claim 4 and chlorin in claim 7; claim text repeatedly refers to chlorins but also includes “phlorin” in claim 7)
- Self-assembly/aggregate behavior
- Conjugates form aggregates >10 kDa in aqueous environments
- Conjugates are sufficiently lipophilic so aggregates dissociate in tissue
- Triplet-state photophysics
- Triplet energy >37.5 kcal/mol
- Redox and quenching constraints
- “not readily oxidized”
- “not capable of physically quenching any required energy state”
- (In claim 10 and 13) spectroscopic identity/characterization constraints
- visible adsorption peaks in water at about 365, 505, 537, 575, 615 nm
- IR adsorption peaks at about 3.0, 3.4, 6.4, 7.1, 8.1, 9.4, 12, 15 microns
- ^13C NMR peak lists in specified solvents with referenced ppm values
Read-through: the patent is aimed at improving photodynamic therapy performance by engineering photosensitizers that show tumor retention while maintaining high triplet energy and suppressing unwanted oxidation or energy-state quenching. The “aggregate >10 kDa in water but dissociate in tissue” feature is a major claim boundary because it distinguishes “pre-assembled” or “transported as aggregates” systems from conventional monomeric photosensitizers.
2. How broad is the scope across porphyrins vs chlorins vs “mixture” compositions?
2.1 Porphyrin-dependent claim spine (claims 1, 10, 13)
- Claim 1: requires conjugates containing two or more covalently-linked porphyrin molecules, with at least one porphyrin unit matching a specified formula (STR3).
- Claim 10: covers “porphyrins” broadly, but still requires:
- tumor localization/retention
- conjugates with at least one porphyrin formula (STR6)
- aggregation >10 kDa in aqueous and dissociation in tissue
- triplet energy >37.5 kcal/mol, not readily oxidized, no physical quenching
- plus detailed adsorption peak identity in visible/IR and ^13C NMR peak lists.
- Claim 13: covers a mixture of porphyrins, where at least some molecules have conjugates of formula (STR7) and include a substituent swap: “one or more hydroxyethyl substituent is replaced by a vinyl group.” Claim 13 also imports the same aggregation, dissociation, triplet energy, oxidation, and quenching limitations plus the same spectroscopic identity requirements.
2.2 Chlorin-dependent claim spine (claims 4 and 7)
- Claim 4: requires two or more covalently-linked chlorin molecules with at least one chlorin matching formula (STR4) and all the same aggregate/triplet/oxidation/quenching/tumor localization requirements.
- Claim 7: similar structure but uses formula (STR5) and contains a likely typographical anomaly: it refers to “phlorin” in the claim text while the formula is written for STR5 and the rest of the functional language mirrors chlorin claims.
2.3 “Mixture” language expands coverage but does not remove core constraints
Claim 13’s “porphyrin mixture” phrasing does not relax the key constraints; it changes the composition definition while still requiring:
- tumor retention vs normal tissue
- aggregation >10 kDa in aqueous
- tissue dissociation
- triplet energy >37.5 kcal/mol
- oxidation/quenching limitations
- and the spectral fingerprint set.
Implication for scope: The patent is broad at the level of “porphyrin vs chlorin family” but narrow at the chemical-and-physical feature level. A generic substitute that is monomeric, non-aggregating, aggregates <10 kDa, or has lower triplet energy would fall outside the independent claim core.
3. What is the claim architecture: method-of-use only, but with chemistry-heavy product-by-characteristics elements?
US 5,145,863 is drafted as methods of contacting biological targets with a composition. Although the legal preamble is method language, the scope is effectively controlled by product-by-characteristics limitations embedded in the composition definition:
3.1 Contacting limitation
Independent claims require “contacting said target materials with an effective amount” of the composition. Dependent claims (3, 6, 9, 12, 15) narrow to administering the composition to a subject.
3.2 Composition definition is the real gate
The composition must be:
- fluorescent and photosensitizing
- tumor-localizing/retaining
- based on covalently linked multi-porphyrin or multi-chlorin constructs
- and must have defined aggregate size behavior and photophysical properties.
Net effect: Even though it is a method-of-use patent, an infringement analysis will hinge on whether an accused formulation has the claimed self-association behavior and photophysical properties, and whether it matches the specific structural formulas and (for certain claims) spectroscopic fingerprints.
4. Where are the strongest claim boundaries for design-around? (Aggregate size, dissociation, triplet energy, oxidation, quenching, and spectra)
4.1 Aggregate size: “aggregates of >10 kDa in aqueous environments”
This is a sharp quantitative boundary. For any challenge or clearance strategy, the primary question is whether the accused photosensitizer:
- forms aggregates larger than 10 kDa under relevant aqueous conditions, and
- whether that aggregation is attributable to covalent conjugates, not just noncovalent micelles.
A defendant can attempt to avoid the threshold by altering:
- linker chemistry,
- hydrophobicity balance,
- charge/solubility profile,
- or formulation environment so the aggregate distribution shifts below 10 kDa.
4.2 Tissue dissociation: aggregates dissociate in tissue
The claim ties lipophilicity to dissociation behavior in tissue. A design-around can try to maintain monomeric distribution in vivo or use different delivery vehicles that prevent the “aggregate-to-monomer in tissue dissociation” dynamic.
4.3 Triplet energy: “>37.5 kcal/mol”
This photophysical threshold can be a practical infringement lever and a design target. A photosensitizer with a lower triplet energy (or that produces less effective triplet generation) would miss this limitation.
4.4 Oxidation and quenching: “not readily oxidized” and “not capable of physically quenching”
These are functional constraints. In litigation, they tend to become technical disputes:
- What oxidation conditions count as “readily”?
- What counts as “physically quenching” the “required energy state”?
A design-around can shift redox stability and energy transfer pathways.
4.5 Spectroscopic fingerprint dependencies in claims 10 and 13
Claims 10 and 13 include detailed adsorption peaks in visible and IR, plus ^13C NMR peak lists.
These constraints narrow infringement scope for those claims but also strengthen enforceability because they supply measurable identity parameters. A competitor can attempt to create a composition whose spectra do not match the listed peaks or whose peak positions/assignments differ due to solvent, concentration, or formulation matrix effects. However, because spectra can be influenced by conditions, the key is whether an accused product can be shown to lack the claimed fingerprint reproducibly.
5. What do the dependent claims add: excipients and subject administration?
- Claims 2, 5, 8, 11, 14: add at least one pharmaceutically acceptable excipient.
- Claims 3, 6, 9, 12, 15: require administering to a subject harboring the target.
These dependent claims do not materially change the composition definition and do not expand chemical scope; they mainly ensure coverage for typical clinical formulation and delivery routes.
6. How would you map infringement elements into a practical claim chart?
Below is an infringement “element checklist” derived directly from the independent claim structure.
| Element from US 5,145,863 |
What an accused product must show |
Typical evidence types |
| Method to destroy/impair target biological materials |
Photodynamic therapy intended to damage biological targets in vivo |
Clinical protocol, mechanism studies |
| Contacting with fluorescent, photosensitizing composition |
Active photosensitizer producing fluorescence and singlet/triplet generation |
Spectroscopy, photophysics |
| Tumor localization and retention vs normal tissue |
Preferential accumulation and retention |
Imaging, biodistribution |
| Composition comprises covalently linked multi-porphyrin or multi-chlorin conjugates |
Chemical structure with 2+ covalently linked porphyrins/chlorins |
Synthesis, characterization, MS/NMR |
| At least one porphyrin/chlorin matches specified formula |
Specific substructure presence |
Structural elucidation |
| Aggregates >10 kDa in aqueous environment |
Self-assembly threshold met |
DLS/MALS, SEC, aggregation assay |
| Dissociation in tissue |
Aggregates break down in tissue relevant conditions |
Serum/tissue mimic experiments |
| Triplet energy >37.5 kcal/mol |
Triplet energy threshold achieved |
Laser flash photolysis, phosphorescence |
| Not readily oxidized |
Oxidation resistance |
Oxidation stability assays |
| Not capable of physically quenching required energy state |
Does not quench energy transfer |
Energy transfer assays |
| (Claims 10/13 only) Visible/IR adsorption peaks at listed positions; ^13C NMR peak lists |
Spectral identity matches |
Spectra with matching peaks under defined conditions |
Most-litigated gates: aggregation size, triplet energy, and the spectral identity elements in claims 10 and 13.
7. What is the patent landscape for this claim type: who typically owns the aggressive photodynamic tumor-retention aggregation tech?
Because only the user-provided claim text is available, only limited landscape assertions can be made without external record lookups. Under those constraints, the actionable conclusion is structural:
- US 5,145,863 covers a specific photochemically engineered conjugate class (multi-porphyrin/chlorin conjugates with aggregate and triplet-energy constraints).
- The landscape risks concentrate around other patents claiming:
- tumor-localizing photosensitizers with multi-porphyrin/chlorin architectures
- aggregation-based delivery and dissociation mechanisms
- triplet-energy optimization and redox/quenching suppression
- spectroscopy-defined species
Business implication: freedom-to-operate analysis must treat this as a chemistry-driven method-of-treatment patent. Even if a competitor uses a different dosing regimen or light delivery scheme, infringement can still be triggered if the accused composition matches the claimed physical chemistry constraints.
8. Which generic or biosimilar-style “entry risk” applies?
This is not a biologic; it is a small-molecule photosensitizer composition patent framed as a method. “Generic entry” risk is therefore tied to:
- whether a competitor can market an equivalent photodynamic composition that avoids the claimed aggregate/triplet/structure/spectral constraints, and
- whether any other patents (device/light regimen, dosing, or formulation) create separate blocks.
Because the claim is highly specific to conjugate formulas and physical properties, the primary entry-risk path is a competitor designing around those constraints rather than simple formulation tweaks.
9. What would a strong validity attack likely target, given this claim wording?
High-level patentability pressure points in claim sets like this typically cluster around:
- Indefiniteness: “not readily oxidized” and “not capable of physically quenching any required energy state” can be attacked as lacking objective boundaries.
- Obviousness: if prior art disclosed tumor-localizing photosensitizers with porphyrin/chlorin covalent linking and photosensitizing function, the novelty may hinge on the quantitative limits (aggregate >10 kDa, triplet >37.5 kcal/mol) and the dissociation behavior.
- Enablement/best mode: if the patent does not sufficiently describe how to achieve the specific aggregate size and spectral fingerprint properties across claimed variations.
Those are structural arguments derived from the phrasing; a full validity evaluation still requires the full specification record and file history, which are not provided here.
10. What is the likely strategic meaning of the spectral requirements in claims 10 and 13?
Claims 10 and 13 add detailed adsorption peaks and ^13C NMR peak lists. Strategically, those elements:
- strengthen claim construction by tying infringement to measurable identity characteristics,
- reduce the ability to argue “it’s equivalent” without matching chemistry or structure,
- shift infringement evidence toward analytical chemistry rather than only biological outcomes.
For enforcement, this makes technical comparison feasible: replicate spectra and compare peak positions/intensity patterns to the claimed set.
Key Takeaways
- US 5,145,863 is a photodynamic tumor-impairment method patent whose real scope is defined by chemistry-heavy composition limitations: multi-porphyrin or multi-chlorin covalent conjugates with >10 kDa aqueous aggregates that dissociate in tissue, plus triplet energy >37.5 kcal/mol and constraints on oxidation and physical quenching.
- Claims 10 and 13 add spectroscopic fingerprint requirements (visible/IR adsorption peaks and ^13C NMR lists), narrowing infringement but strengthening evidence for identity-based comparisons.
- Dependent claims mainly add excipient inclusion and subject administration, without materially expanding the composition scope.
- The strongest design-around levers are likely the quantified/functional gates: aggregate size, triplet energy, redox behavior, energy quenching, and (for spectra claims) matching the specified spectral peak patterns.
FAQs
1. What element in US 5,145,863 most directly distinguishes it from ordinary monomeric photosensitizers?
The requirement that the covalent conjugates form aqueous aggregates >10 kDa that dissociate in tissue, coupled with triplet energy >37.5 kcal/mol and the oxidation/quenching limitations.
2. Do the dependent excipient claims expand chemical scope beyond the independent claims?
No. Claims adding “at least one pharmaceutically acceptable excipient” mainly cover typical formulations while keeping the same core conjugate/photophysical/aggregration constraints.
3. Can a competitor infringe without matching the exact porphyrin/chlorin structural formulas?
For the independent claims that incorporate those formula constraints, infringement requires meeting those structural formula limitations. Where claims do not include full formula specificity (in general method language), the composition is still constrained by the listed formulas in the claim text.
4. How do the ^13C NMR and adsorption peak requirements affect infringement risk?
They narrow the composition identity under claims 10 and 13 by adding measurable spectral constraints that can be tested against analytical data.
5. Does the method claim allow competitors to avoid liability by changing light dosing or illumination parameters?
Not if the accused composition still matches the claimed chemistry and photophysical behavior and is used to “destroy or impair” the target biological materials. The claim text provided focuses on the composition attributes more than on light regimen details.
References (APA)
- United States Patent 5,145,863. (Claim text provided).
